BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. rs2476601, DNMT1, Angiogenesis, Influenza, Embryo, Personalized medicine, Valproic acid)
Bookmark Forward

QuickView for STI571 (compound)


Genetic Markers

Most Correlated Genes

  1. IL4I1
  2. CD83
  3. LTA
  4. Mir155
  5. RAG1
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. PILON_KLF1_TARGETS_DN
  2. PUJANA_BRCA1_PCC_NETWORK
  3. DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP
  4. heterocycle metabolic process
  5. cellular aromatic compound metabolic process
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Expression data for program activation by IR-induced DNA breaks in G1 phase preB cells
  2. Differentiation-induced gene expression in IL-7-dependent and BCR-ABL1-transformed pre-B cells
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cel…
  2. Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the S…
  3. Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combina…
  4. STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis.
  5. PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukem…
  2. Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
  3. Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participant…
  4. Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant I…
  5. STI571 in Treating Patients With Recurrent Leukemia
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.